Search academic texts

Information × Registration Number 0218U000382, 0117U001050 , R & D reports Title Optimization of the ovarian cancer diagnostics by substantiating the possibility of using the HE-4 tumor marker popup.stage_title Head Sukhina O.M., Mikhanovskiy О.A., Registration Date 26-01-2018 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2 Object of study: malignant tumors of ovaries. Objective: to improve the accuracy of ovarian cancer diagnosis and to predict its relapses by determining the clinical informativity of the tumor-associated marker HE-4. Methods and apparatus: roentgenological, morphological, clinical, instrumental, statistical; immunoanalyzer-photometer electro-chemiluminescence immunoassay cobas e 411. Theoretical and practical results: in this investigation was established clinical informativity of the tumor-associated marker HE-4, which is higher by 1.8 times compared with CA-125, for the diagnosis of malignant tumors of the ovaries (MTO). It was determined that the presence of ascites affects the initial level of tumor markers' expression, increasing HE-4 by 3.7 times, and CA-125 by 2.1 times. It was found that in the ascites form of ovarian tumors, the sensitivity of HE-4 is higher only in patients over 50 years of age compared with CA-125. Clarified scientific data on the accuracy of the HE-4 marker, which is higher than CA-125 for all histological types of malignant tumors of the ovaries (especially in cases of mucinous, endometrioid, and cellular cancer). It was found that the abovementioned marker is a stage dependent one. Novelty: for the first time it has been proved that the initial level of HE-4 above 500 pmol/l is an indicator of the risk of recurrence of up to 1 year, on the basis of which a method for predicting the occurrence of relapses in patients with MTO and establishing the term of a non-recurring period was developed. It has been established that the specificity of the inhibitor of proteases HE-4 exceeds the specificity of oncofetal protein CA-125 by 1.5 times, which allows recommending its use in the diagnosis of MTO. The effectiveness of implementation: primary diagnosis of patients with tumors of the ovary with tumor-associated HE-4 increases the detection rate of the tumor in the early stages by 1.8 times, which reduces the number of CTx cycles from 8-10 to 6, which saves about 8 thousand UAH on the treatment of one patient. Field of use: oncology. Product Description popup.authors Артамонова Н.О. Міхановський О.А. Немальцова К. В. Сухін В.С. Сухіна О.М. Харченко Ю.В. popup.nrat_date 2020-04-02 Close